(IN BRIEF) Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- and program-based payments. The partnership, built on Evotec’s AI-driven drug discovery platforms and BMS’s CELMoD™ technology, continues … Read the full press release →
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged AI drug discovery, biotech partnerships, Bristol-Myers Squibb, CELMoD, Cord Dohrmann, E3 ligase, Evotec, first-in-class, milestone payments, molecular glue degraders, oncology, PanOmics, partnership, pharmaceutical R&D, protein degradation, targeted therapies, unmet medical needs